cgm device ipro2 professional (Medtronic inc)
90
Structured Review
Medtronic inc
cgm device ipro2 professional
Cgm Device Ipro2 Professional, supplied by Medtronic inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipro2+cgm+system/ipro2+cgm+system/pm39615596-91-16-18
Average 90 stars, based on 1 article reviews
Cgm Device Ipro2 Professional, supplied by Medtronic inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipro2+cgm+system/ipro2+cgm+system/pm39615596-91-16-18
Average 90 stars, based on 1 article reviews
cgm device ipro2 professional - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Interventions in women with type 2 diabetes mellitus in the pre-pregnancy, pregnancy and postpartum periods to optimise care and health outcomes: A systematic review. Article Snippet: There was a reduction in the primary outcomes of NICU admission (metformin 43.8% vs. metformin + insulin 23.3% vs. insulin 69.9%, p < 0.01) and neonatal hypoglycaemia (metformin 25.0% vs. metformin + insulin 7.8% vs. insulin 30.0%, p < 0.01) in the metformin (and metformin/insulin) treated group, as well as a reduction in a number of secondary outcomes including gestational hypertension and weight gain, and an increase in SGA infants.18 Refuerzo et al reported no differences between groups in their small pilot study.19 Two studies investigated the impact of CGM use in women with Type 2 diabetes (embedded with other types of diabetes) on fetal growth compared to self- monitoring of blood glucose (SMBG); Secher et al intermittently utilised a first- generation Guardian Real- Time sensor (Medtronic, Northridge, California), recruiting individuals with both Type 1 and Type 2 diabetes between 2009 and 2011 at ≤14 weeks gestation (n = 154; 31 with Type 2 diabetes).17 Voormolen et al utilised the iPro2 (Medtronic, Northridge, California) CGM system intermittently in individuals with pre- existing diabetes and gestational diabetes, recruiting at <16 weeks' gestation (n = 300; 81 with Type 2 diabetes).20 Neither study noted significant differences in either primary or secondary outcomes in women randomised to CGM compared to standard treatment. Article Title: Interventions in women with type 2 diabetes mellitus in the pre‐pregnancy, pregnancy and postpartum periods to optimise care and health outcomes: A systematic review Article Snippet: Voormolen et al utilised the iPro2 (Medtronic, Northridge, California) CGM system intermittently in individuals with pre‐existing diabetes and gestational diabetes, recruiting at <16 weeks' gestation ( n = 300; 81 with Type 2 diabetes). Article Title: Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes Article Snippet: At the baseline visit, the iPro2 CGM system (Medtronic Inc.) with the Enlite sensor was inserted into the abdominal subcutaneous adipose tissue. Article Title: Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. Article Snippet: Continuous glucose monitoring (CGM) was conducted using the iPro2 CGM system (Medtronic Inc.) for blinded assessment. |
